Ongoing investigations into cretostimogene are expanding across multiple patient populations and therapeutic strategies, building a robust and diverse clinical portfolio. Current studies include ...

The final results of the BOND-3 trial, recently presented at major urology conferences, have reinforced the promise of intravesical cretostimogene as a treatment for patients with BCG-unresponsive CIS ...

Key Takeaways Surgical therapy for ED is rare, with only 1.1% of patients undergoing procedures in community-based urology practices in the US. Racial and ethnic disparities exist in the time to ...

Former President Joseph R. Biden’s recent diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has offered a sobering reminder that prostate cancer remains a growing concern ...

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Key Takeaways Lutetium (177Lu) rhPSMA-10.1 showed higher radiation doses in tumors than in normal organs, indicating a favorable therapeutic index in mCRPC patients. The phase 1 trial demonstrated a ...

At the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada, Amy E. Krambeck, MD, presented a talk titled, “Innovation in endourology & building successful clinical programs.” In ...

Key Takeaways A genomic test predicts chemotherapy resistance using chromosomal instability signature biomarkers across multiple tumor types, including metastatic prostate cancer. The test is designed ...

Key Takeaways Detalimogene voraplasmid received RMAT designation, expediting its development for high-risk BCG-unresponsive NMIBC with CIS. The investigational therapy is a non-viral gene-based ...

Specifically, data showed that transperineal prostate biopsy offered greater utility (+0.06 QALY per 1000 patients) and lower cost (-$63,170 per 1000 patients) compared with transrectal prostate ...

In a recent interview with Urology Times ®, David Stanley, MD, FACS, discussed current trends and unmet needs in the treatment of patients with kidney stones. Stanley is a urologic surgeon at Georgia ...

Overall, data showed that darolutamide extended the time to deterioration in FACT-P total score (overall well-being). The median time to deterioration was 16.6 months in the darolutamide arm vs 11.5 ...